- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04572074
Virtual Reality for Cancer Pain Management
Pilot Study to Evaluate Virtual Reality for Cancer Pain Management
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects hospitalized at MedStar Washington Hospital Center will be considered for enrollment in this study if able to provide consent, at least 18 years old, and report moderate-severe pain (at least 4 out of 10 where pain is rated on a Likert scale between zero and 10) in the previous 24 hours. Subjects will be excluded if they already use VR for personal use, have intractable nausea/vomiting, history of motion sickness, history of seizures or epilepsy, have cranial structure abnormalities that prevent use of VR headset, are currently enrolled in a palliative care or pain management study, and/or are on contact isolation. Institutional review board approval will be sought and informed consent will be conducted before enrolling every patient.
After consenting to participate, in addition to usual pharmacologic pain management, 128 patients will be randomized with a 1:1 ratio to receive either one 10-minute VR session, or one 10-minute 2-dimensional guided-imagery session. The investigators believe this sample size is easily achievable given current palliative consult volumes for patients with cancer at the study institution (see above); this sample size accounts for estimates that only approximately half of eligible subjects are interested in trying VR therapies.
VR sessions will be administered using the Facebook (Facebook Inc., Menlo Park, CA) Oculus Quest VR and Touch controllers. This equipment was selected because it is portable and can be set up at the bedside in private or shared patient rooms. The hand controllers facilitate immersive, interactive VR experiences for patients who may be bedbound or have limited mobility in the inpatient setting. The VR software, Forest of Serenity (Holosphere VR ®, Birmingham, UK) is a free application that features seven non-violent mini-games in a carnival environment that can be played in a seated or fixed position.
The guided-imagery session depicts a peaceful walk through a forest with instrumental background music and 2-dimensional imagery. Subjects will watch the guided imagery video on a portable tablet for 10 minutes, the same duration as the VR intervention. Subjects in both arms will continue to receive standard pharmacologic pain management. Because of the nature of the compared interventions, subjects and researchers cannot be blinded to intervention.
The primary outcome measure will determine the impact of distraction therapy (either VR therapy or 2-dimensional guided imagery) on self-reported pain experience. Self-reported pain experience remains the standard for clinical pain research. Secondary outcomes will measure impact of each distraction therapy on general distress level, general quality of life, and satisfaction with pain management. For patients receiving opioid therapies for pain in the preceding 24 hours, the investigators will also evaluate "as needed" opioid use.
Following consent and randomization, subjects will complete surveys on electronic tablets to provide baseline data on pain scores, general distress, general quality of life, and satisfaction with pain management. Pain will be assessed using the Brief Pain Inventory-Short Form (BPI-SF, modified to assess symptoms in the last 24 hours) that includes a 0-10 Likert scale for self-reported pain as well as information about pain location, quality, and interference of pain on daily living. General distress will be measured using the Distress Thermometer (a Likert scale measuring from No Distress to Extreme Distress, where "distress" is defined by the patient). General quality of life will be measured using the Functional Assessment in Chronic Illness-Therapy in Palliative Care 14-item (FACIT-Pal 14) scale that measures non-pain symptoms and general well-being. Subjects will also be surveyed regarding comfort with technology and self-directed use of passive and active distraction therapies.
After completion of baseline surveys, subjects will be administered either VR therapy for 10 minutes or 2-dimensional guided imagery for 10 minutes. For both arms, a member of the research team will educate the subject on the technology and assure comfort with use, remaining outside the room but nearby during the actual 10 minutes.
Following the distraction therapy, subjects will be re-surveyed BPI-SF, FACIT-Pal 14, and Distress Thermometer. Both groups will also be surveyed and given semi-structured interviews regarding acceptance of and satisfaction with the distraction therapy intervention itself and its thematic content. Subjects randomized to VR therapy will be surveyed regarding level of immersion of the VR experience (Immersive Tendencies Questionnaire, http://w3.uqo.ca/cyberpsy/docs/qaires/immersion/ITQ_va.pdf).
In order to evaluate any residual effects of the distraction therapy, enrollees will be re-surveyed BPI-SF, FACIT-Pal 14, Distress Thermometer, and pain management satisfaction questions on the following day.
This study will reach 80% power to detect a difference of 1 unit in the pain score measure between the 2 groups using a two-sample t-test with equal variance at a two-sided alpha=0.05 and assuming a within-group standard deviation of 2 for each group. Sample size calculations were conducted in PASS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- hospitalized, with primary diagnosis of cancer
- age 18 and older
- report moderate-severe pain (at least 4 out of 10 where pain is rated on a Likert scale between zero and 10) in the previous 24 hours
Exclusion Criteria:
- already use VR for personal use
- intractable nausea/vomiting
- history of motion sickness
- history of seizures or epilepsy
- have cranial structure abnormalities that prevent use of VR headset
- currently enrolled in a palliative care or pain management study
- on contact isolation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Arm 1 (Guided imagery)
10 minutes of guided imagery experience
|
10 minutes of guided imagery experience
|
EXPERIMENTAL: Arm 2 (Virtual reality)
10 minutes of virtual reality experience
|
10 minutes of virtual reality experience
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in self-reported pain score from baseline to immediately after assigned intervention
Time Frame: Baseline and again immediately after assigned intervention
|
Likert scale 0 (no pain) to 10 (worst pain)
|
Baseline and again immediately after assigned intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in self-reported distress from baseline to immediately after assigned intervention
Time Frame: Baseline and immediately after intervention, 24 hours after intervention
|
National Comprehensive Cancer Network Distress Thermometer
|
Baseline and immediately after intervention, 24 hours after intervention
|
Change in self-reported quality of life from baseline to immediately after assigned intervention
Time Frame: Immediately after assigned intervention
|
Functional Assessment in Chronic Illness-Therapy in Palliative Care 14-item scale (FACIT Pal 14 scale) -- subject replies to 14 questions about quality of life issues with responses in 5-point Likert scale (0 = not at all; 4 = very much), total score range 0-56
|
Immediately after assigned intervention
|
Acceptability of intervention ("Would you use this intervention again?") -- this single question designed for this study
Time Frame: Immediately after intervention
|
Single best answer: subjects choose between two choices, "Yes" or "No"
|
Immediately after intervention
|
Level of immersion experienced in virtual reality arm
Time Frame: Immediately after intervention (virtual reality arm only)
|
Immersive Experience Questionnaire
|
Immediately after intervention (virtual reality arm only)
|
Ease of intervention ("How easy was this technology for you to use?") -- this single question designed for this study
Time Frame: Immediately after assigned intervention
|
Single best answer to this question: subjects choose between "easy," "normal," or "difficult"
|
Immediately after assigned intervention
|
Change in self reported distress from baseline to Immediately after assigned intervention
Time Frame: Immediately after assigned intervention
|
National Comprehensive Cancer Network Distress Thermometer -- subject rates distress at that point in time on Likert scale 0-10 (0 = no distress; 10 = worst distress)
|
Immediately after assigned intervention
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-240
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Guided imagery
-
University of MinhoFoundation for Science and Technology, PortugalActive, not recruitingDiabetes Mellitus | Diabetic Foot UlcerPortugal
-
William Beaumont HospitalsWithdrawnChronic Pain | Pelvic PainUnited States
-
Universiti Sains MalaysiaCompletedFunctional Gastrointestinal DisordersMalaysia
-
University of MinhoFoundation for Science and Technology, PortugalCompletedDiabetes Mellitus | Diabetic Foot UlcerPortugal
-
Dicle UniversityCompleted
-
University of TorontoDalhousie University; AWHONN Canada, with Canadian Nurses Foundation Nursing... and other collaboratorsCompletedHypertension | Pre-Eclampsia | Hypertension, Pregnancy-InducedCanada
-
Kenneth M Peters, MDTerminatedPelvic Pain | Cystitis, InterstitialUnited States
-
Baskent UniversityHacettepe UniversityRecruitingChemotherapy-induced Nausea and Vomiting | Pediatric CancerTurkey
-
Menekşe Nazlı AKERNot yet recruiting
-
Menekşe Nazlı AKERCompleted